Friday, September 4, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 8, 2026

Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight

View original at globenewswire.com
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight New York, USA, June 08, 2026 (GLOBE NEWSWIRE) -- Alcohol Use Disorder Market Set to Expand at a 12.1% CAG…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Although several AUD therapies have been approved, treatment uptake remains substantially low, leaving a significant proportion of affected individuals untreated

    60% confidence

  • There were 25.6 million 12-months diagnosed prevalent cases of AUD in the US in 2025, which are projected to decrease by 2036

    60% confidence

  • The AUD market is projected to expand at a 12.1% CAGR during the forecast period 2026–2036

    60% confidence

  • The exploration of novel mechanisms in AUD treatment such as 5-HT3 antagonism, NOP receptor modulation, mGluR5 NAM activity, and dual GLP-1/glucagon receptor agonism highlights significant opportunities for other developers to enter a space with high unmet need and to differentiate their pipelines through innovative, non-traditional targets

    60% confidence

  • The United States accounted for the largest alcohol use disorder treatment market size in 2025 compared to EU4, UK, and Japan

    60% confidence

  • The 12-month diagnosed prevalence of AUD in the US declined from approximately 10.6% in 2021 to approximately 9.7% in 2025

    60% confidence

  • Brenipatide represents Eli Lilly's expansion into indications beyond obesity, including alcohol use disorder, opioid dependence, and asthma

    60% confidence

  • Growing awareness, early AUD diagnosis, rising focus on harm reduction and personalized care, and strong clinical trial activity are expected to drive significant AUD market growth

    60% confidence

  • The AUD market size was USD 1.1 billion across the 7MM in 2025

    60% confidence

  • Altimmune expects to announce topline results from the RECLAIM Phase II trial evaluating pemvidutide in AUD in 2026

    60% confidence

  • The AD04 patent, once granted, is expected to protect Adial's core assets through at least 2045

    60% confidence

  • VIVITROL (naltrexone) holds the highest US AUD market share in 2025, while by 2036, AD04 is projected to capture the largest market

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight — Source | Via News | Via News